In this book, leading-edge investigators offer effective strategies to improve current antidepressive therapies and suggest molecular, biological, and genetic approaches that will lead to the development of novel antidepressants. The contributors' critical reviews and commentaries illuminate our understanding of the mechanism(s) responsible for antidepressant action. The book's goal is to move beyond current biogenic amine-based concepts and therapies to the development of new and improved antidepressants that are more effective and have a more rapid onset than current.

Inhalt
1 Strategies to Optimize the Antidepressant Action of Selective Serotonin Reuptake Inhibitors.- 2 Antidepressant Properties of Specific Serotonin-Noradrenaline Reuptake Inhibitors.- 3 5-HT-Moduline: Novel Therapeutic Strategy for Antidepressant Action.- 4 Reversible Inhibitors of Monoamine Oxidase A (RIMAs): Where Can We Go from Here?.- 5 Calcium Channel Antagonists in Mood Disorders.- 6 Functional NMDA Antagonists: A New Class of Antidepressant Agents.- 7 Is an Adaptation of NMDA Receptors an Obligatory Step in Antidepressant Action?.- 8 NMDA Receptors and Affective Disorders.- 9 The Potential Contribution of Sigma Receptors to Antidepressant Actions.- 10 A Role for CREB in Antidepressant Action.- 11 Antidepressants: Beyond the Synapse.- 12 Animal Models to Detect Antidepressants: Are New Strategies Necessary to Detect New Agents?.- 13 Molecular Strategies to Novel Antidepressant Discovery.